Skip to main content
Clinical Trials/NCT03340688
NCT03340688
Recruiting
Not Applicable

Cervical Cerclage for Preventing Spontaneous Preterm Birth in Twin Pregnancies With Transvaginal Ultrasound Cervical Length ≤ 15mm: a Study Protocol for a Randomized Clinical Trial

Thomas Jefferson University8 sites in 4 countries200 target enrollmentJune 22, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Twin Pregnancy With Antenatal Problem
Sponsor
Thomas Jefferson University
Enrollment
200
Locations
8
Primary Endpoint
Preterm delivery less than 34 weeks
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

This is a multicenter randomized study designed to determine if ultrasound indicated cerclage reduces the incidence of spontaneous preterm birth <34 weeks in asymptomatic women with twin gestations and cervical length ≤15mm, diagnosed by transvaginal ultrasound between 16 to 23 6/7 weeks of gestation.

Detailed Description

Twin pregnancies have 59% incidence of preterm delivery (before 37 weeks of gestation), with increased perinatal mortality and neonatal morbidity. No therapy has proven effective in preventing preterm birth in twins. The transvaginal cervical length (TVCL) performed before 24 weeks have been determined to be the best tool to identified women with twin pregnancy at risk of preterm birth (PTB). When short TVCL is identified before 24 weeks, the risk of preterm birth is 60%-70% for TVCL ≤25mm and 80%-90% for TVCL ≤15mm. There are a small number of case reports of cervical cerclage in twin pregnancies with cervical length ≤15mm that suggest decreased preterm birth by 80%. The investigators' objective is to determine if ultrasound indicated cerclage in reduces the incidence of spontaneous preterm birth \<34 weeks and improve perinatal outcome in asymptomatic women with twin gestations and cervical length ≤15mm between 16 to 23 6/7 weeks of gestation.

Registry
clinicaltrials.gov
Start Date
June 22, 2017
End Date
June 2025
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Pregnant women more than 18 years of age (limits the participants to female gender)
  • Diamniotic twin pregnancy
  • Asymptomatic
  • Transvaginal cervical length ≤ 15 mm between 16-23 6/7 weeks gestation

Exclusion Criteria

  • Singleton or higher order than twins multiple gestation
  • Transvaginal cervical length \>15mm
  • Cervical dilation with visible amniotic membranes
  • Amniotic membranes prolapsed into the vagina
  • Fetal reduction after 14 weeks form higher order
  • Monoamniotic twins
  • Twin-twin transfusion syndrome
  • Ruptured membranes
  • Major fetal structural anomaly
  • Fetal chromosomal abnormality

Outcomes

Primary Outcomes

Preterm delivery less than 34 weeks

Time Frame: at delivery

Incidence of preterm birth less than 34 weeks (any indication)

Secondary Outcomes

  • Interval between diagnosis and delivery(at delivery)
  • Neonatal death(Between birth and 28 days of age)
  • Spontaneous preterm birth rates(at delivery)
  • Preterm delivery less than <32 weeks, <28 weeks, or <24 weeks(at delivery)
  • Mean gestational age at delivery(at delivery)
  • Premature rupture of membranes(at delivery)
  • Chorioamnionitis(at delivery)
  • Composite adverse neonatal outcome(Incidence between birth and 28 days of age)
  • Maternal death(Between birth and 6 weeks postpartum)
  • Birth weight at birth(at delivery)
  • Gestational age at spontaneous rupture of membranes(at delivery)

Study Sites (8)

Loading locations...

Similar Trials